Thrombolytic therapy in acute myocardial infarction

Area of Science:

• Cardiology
• Thrombosis Research
• Pharmacology

Background:

• Acute myocardial infarction (MI) treatment has advanced, yet mortality rates remain significant.
• Current recombinant tissue-type plasminogen activator (rt-PA) regimens show a 6.3% 30-day mortality and 1.5% fatal cerebral hemorrhage risk.
• Optimal patient prognosis hinges on early thrombolytic agent infusion and rapid, sustained reperfusion (TIMI grade 3 flow).

Purpose of the Study:

• To explore strategies for improving short- and long-term prognoses in acute MI patients.
• To identify prerequisites for optimal ventricular function preservation and favorable outcomes.
• To evaluate the potential of novel treatment strategies in enhancing thrombolysis efficacy.

Main Methods:

• Review of existing treatment protocols for acute myocardial infarction.
• Analysis of factors influencing reperfusion rates and thrombolysis in myocardial infarction (TIMI) flow.
• Exploration of emerging therapeutic approaches, including accelerated dosages and combination therapies.

Main Results:

• Early intervention and achieving TIMI grade 3 flow are critical for better outcomes.
• Persistent thrombolysis in myocardial infarction (TIMI) grade 3 flow is a key predictor of favorable prognosis.
• Newer treatment strategies hold promise for improved efficacy in acute MI.

Conclusions:

• Further improvements in acute MI outcomes necessitate optimizing thrombolytic therapy timing and efficacy.
• Accelerated dosage regimens, combination therapies, and novel agents may enhance thrombolysis.
• Achieving rapid and sustained reperfusion remains a primary goal for preserving cardiac function and reducing mortality.